Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396113 | 0.93 | CNR2 (0.32) | KDM4ENPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29396595 | 0.92 | KDM4E (0.33) | KDM4E | |
| SCHEMBL29435399 | 0.87 | — | — | |
| SCHEMBL30619640 | 0.87 | — | — | |
| SCHEMBL30288311 | 0.86 | NPC1 (0.32) | NPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29394228 | 0.85 | CNR2 (0.35) | KDM4E | |
| SCHEMBL30619617 | 0.83 | RARG (0.31) | — | |
| SCHEMBL22321053 | 0.82 | CNR2 (0.35) | KDM4ENPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29435416 | 0.82 | CNR2 (0.35) | KDM4ENPC1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL29435387 | 0.82 | CNR2 (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724505-A1 | NON-COORDINATED ALKYLALUMINUM FREE ANION MODIFIED ALUMOXANES AND METHODS THEREOF | ExxonMobil Technology and Engineering Company (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4196507-B1 | CYCLIC CONTAINING POLYMER COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND PROCESS FOR PRODUCTION THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024253831-A1 | NON-COORDINATED ALKYLALUMINUM FREE ANION MODIFIED ALUMOXANES AND METHODS THEREOF | ExxonMobil Technology and Engineering Company (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20230287156-A1 | Polyethylene Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4196507-A1 | CYCLIC CONTAINING POLYMER COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND PROCESS FOR PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4103629-A1 | POLYETHYLENE COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND HOMOGENEOUS PROCESS FOR PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11254763-B2 | Transition metal bis(phenolate) complexes and their use as catalysts for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254763-B2 | Transition metal bis(phenolate) complexes and their use as catalysts for olefin polymerization | CCNT1, CCNA1, CCNE2 | KDM4E 1895/4885NPC1 3941/4885TSHR 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.